BIOLASE, Inc. announced findings from a 12-month follow-up to a clinical trial performed at The McGuire Institute(TM). The findings will be published in the November 2023 issue of the Journal of Periodontology. The pioneering study was designed to meet the stringent American Association of Periodontology Best Evidence Consensus (BEC) standards, and is the first-of-its-kind study to compare BIOLASE's REPAIR(R) Perio protocol to the traditional minimally invasive surgical technique (MIST) treatment of moderate to severe generalized periodontitis.

Key highlights include: Clinicalllly Proven and Validated by Scientific Research The stu confirms that BIOLASE's Waterlase e REPAIR(R) perio protocol has similar and sustainable clinical outcomes as compared to traditional MIST in treating intrabony defects over the 12-month study thus reaffirming rigorous scientific research and the laser's clinical efficacy. Enhanced Positive Patient Experience: Patients who underwent BIOLASE's Waterlases REPAIR(R)Perio laser treatment reported significantly better patient-reported outcomes (PROs) at six months. These findings show that patients experienced less pain, reduced bleeding, and minimal discomfort, indicating a patient-friendly approach to periodontal care.

Intrabony periodontal defects are pockets that form between the tooth and bone and can lead to tooth loss. The Waterlase laser works by vaporizing the diseased tissue and stimulating the body to produce new bone and gum tissue.